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EDITORIAL

Tumor Response Evaluation Criteria: Standardization Ensures Success
Maseeh uz Zaman1, Nosheen Fatima1 and Mahwish Sajid2

Cancer-related mortality is growing rapidly. It is expected
that in years to come, cancer will become the most
common cause of death worldwide. Cancer-related
therapies are not only expensive but associated with
morbidities; and the tumor shrinkage with recently
introduced therapies is seen in only 10-15% patients.1
However, in recent days various therapies have
improved survival rate and outcome of patients with
certain cancers like childhood malignancy and
lymphomas. Imaging plays an important role by helping
the oncologists and guides them whether to continue,
change or abandon a treatment, depending upon the
response of the tumor. Response could be evaluated by
physical examination or by using anatomical or
functional imaging, and it could be assessed either
qualitatively like the visual analysis or quantitatively
using digital images and computer algorithms.

In early 70's when computerized tomography (CT) was
not freely available, Moertel and Henley2 presented a
study in which they employed 16 experienced
oncologists and assessed the consistency in palpation
of 12 pairs of fake masses. For 50% reduction in
perpendicular diameter of tumor as response, the interobserver variability was 7-8%. However, for a cut-off of
25% reduction in tumor size as response, they observed
an inter-observer variability of 19-25%. Therefore, they
recommended that greater than 50% decline in the
perpendicular tumor diameter should be considered as
response. In late 70’s with the wider availability of CT
scan, the World Health Organization (WHO) presented
tumor response criteria based on the product of
2 perpendicular diameters (bi-dimensional criteria).3
According to these criteria, the tumor responses were
categorized as complete response when there was
disappearance of tumor at least 4 weeks after treatment;
partial response when ≥ 50% decrease in some of
products; and no change when neither partial nor
complete response. Progressive disease was defined as
≥ 25% increase in sum of product with or without
appearance of new lesion. However, WHO criteria had
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severe limitation of overestimation of the progressive
disease because an increase of 11% in each dimension
gives a product of 25% (false positive). Other limitations
were that there was no mention of the number of lesions
that should be measured or the smallest lesion that
should be considered as a measurable one.

In the year 2000, a comprehensive response evaluation
criteria in solid tumor (RECIST) was published which
was revised (RECIST 1.1) in 2009.4,5 These criteria in
contradistinction to WHO criteria recommended using
the single longest diameter of tumor (uni-dimensional)
and sum of longest dimensions was recommended to
categorize response evaluation. RECIST and RECIST
1.1 have addressed most of the limitations of WHO
criteria as well. RECIST 1.1 recommends measuring
maximal 5 target lesions and 02 lesions per organ
(target non-nodal lesion: ≥ 10 mm in the longest
dimension; target node: ≥ 15 mm short axis dimension);
and ≥30% declining the sum of the longest dimension is
considered as partial response. Revised RECIST 1.1
criteria also recommend an increase in 20% in sum of
the longest dimension with at least 5 mm absolute
increase in size of a lesion to qualify for progressive
disease.
The basic limitations of RECIST criteria are variability in
the measurement of tumor sizes by various readers and
its application in non-measurable diseases like
mesothelioma or bone marrow metastasis. Furthermore,
with the introduction of the cytostatic therapy (Imatinib in
GIST and Sorafenib in Hepatoma) tumor shrinkage is
not expected in the early phase of the treatment. Having
a residual mass at completion of the chemotherapy is
not an unusual finding and poses difficulty to assess the
response solely on anatomical criteria.

Histopathologically, these residual tumor masses may
be composed of non-viable fibrotic tissue or having
subclinical viable tumor tissue. This has opened vista for
metabolic response criteria. History of metabolic
response assessment dates back to 1988 when Israel
et al. claimed disappearance of Gallium-67 as an
indicator of remission of Non-Hodgkin lymphoma
(NHL).6 In 1993, Richard Wahl shared his experience of
using serial 18-fluorodeoxyglucose (18FDG) in a patient
with breast cancer who responded to chemo-hormone
therapy with a progressive decline in 18FDG uptake.7
Based on these evidences, it was found that there is a
strong correlation between 18FDG uptake and metabolic
tumor burden and, therefore, changes in the 18FDG
uptake rather than the tumor size must be considered as
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a metabolic indicator for tumor response. Presently,
18FDG because of its wider availability is the most
commonly used agent for evaluation of metabolic tumor
response. 18FDG based assessment could be made
either visually or qualitatively, which requires static
image but no blood sampling; or quantitatively, which
needs acquisition of the dynamic imaging and arterial
blood sampling (cumbersome); and despite being
accurate, is not used by most of the clinical centers
worldwide. Another method, is the semiquantitative
method which requires static whole body imaging
without blood sampling and the ratio of tumor 18FDG
uptake with injected 18FDG dose normalized to the body
weight (BW) or lean body mass (LBM) or body surface
area (BSA) is calculated. This ratio is called
standardized uptake value (SUV), which along with
qualitative (visual) assessment is the most commonly
used strategy for assessment of metabolic tumor
response.

The first metabolic response criteria were published by
European Organization of Research and Treatment of
Cancer (EORTC), which was published by Young et al.8
These criteria emphasized upon the patient preparation,
time of scans after the last chemotherapy and use of
SUV normalized to the BSA; and for tumor sampling,
SUVmax and SUVmean were recommended to be used.
Complete metabolic response (CMR) was defined as
complete disappearance of tumor activity to the
background level while the partial metabolic response
(PMR) was defined as >15% decline in SUVmax after the
first or more >25% decline after 2nd chemotherapy while
the reduction in the extent of the uptake is not required.
Stable metabolic disease (SMD) was defined as
increase in SUVmax <25% or declining in SUVmax >15%
decline but no increase in extent of uptake. Progressive
metabolic disease (PMD) was defined as increase in
SUVmax >25%, increase in extent >20%, or appearance
of a definite new 18FDG avid lesion. However, the
limitation of EORTC criteria included significant changes
in the individual tumor SUVs and the use of the
retrospective data having limited number of patients,
tumor types and treatment strategies.

Richard Wahl presented a comprehensive Positron
Emission Response Criteria In Solid Tumor (PERCIST)
in 2009.1 PERCIST criteria stress upon the utilization of
SUV which is normalized to LBM (SUVlbm = SUL) and
use SULpeak (measured over 1.3 cm3 circle) for tumor
sampling and not SUVmax (calculated upon single pixel
and subject to image noise) as recommended by
EORTC criteria. PERCIST also defined the measurable
lesion having a SULpeak >1.5 x Liver SULmean +2
standard deviation. It recommends measuring the single
hottest lesion for response evaluation. However,
measurement up to 5 lesions may be performed to build
a prospective data. PERCIST strongly emphasized upon
standardization of imaging protocol and recommends
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that hepatic SULmean, uptake time and injected 18FDG
doses of 2 studies must be ±20%, ±15 minute and ±10%,
respectively. It also stresses upon the utilization of the
same scanner as difference between calibrations of two
scanners could result in variation in SULpeak values.
CMR is defined as visual disappearance of all of
metabolically active tumors; PMR as decline of >30%
(0.8 unit) of SULpeak between intensities of hottest lesions
pre- and post-therapy (which may not be the same
lesion) and no new lesion; SMD as no CMR/PMR/RMD;
PMD as increase of >30% (0.8 unit) of SULpeak or
appearance of a definite 18FDG avid malignant lesion.
Limitations of PERCIST include getting SULpeak (as
calculation of LBM is difficult) and lack of standardization
of imaging protocols. According to one study published
in 2011, <50% the studies could not meet
standardization criteria due to the use of different
scanners at Johns Hopkins University. Because of these
limitations, PERCIST has been struggling to gain
popularity in oncological functional imaging.

However, in 18FDG-avid lymphomas, metabolic response
criteria have been widely used worldwide. Because of
the high diagnostic accuracy of 18FDG PET/CT in
Hodgkin's lymphoma and many diffuse large B-cell
lymphomas (DLBCL), bone marrow biopsy can be
avoided. 18FDG PET/CT is used for staging and interim
PET [iPET] (after 2 cycles) and end of treatment [ePET]
18FDG PET/CTs are used for response evaluation.
However, routine surveillance scan is not recommended
due to high incidence of false positive findings resulting
in unjustified investigations. Although there are many
response evaluation criteria published by many
societies, Deauville-5-point score (D-5PS) is the most
commonly used criteria worldwide.9 Score 1 means no
uptake and score 2 defined as uptake equal or less than
mediastinal blood pool activity. Score 1 and 2 are
construed as CMR for both iPET and ePET. Score 3 is
defined as uptake greater than mediastinal blood pool
activity but equal or less than liver. For iPET, it is
interpreted as CMR but for ePET good response. Score
4 is defined as activity moderately greater than liver
(1 liver SUVmax) and score 5 as markedly greater than
liver (>2 liver SUVmax) uptake with or without a new
definite lesion. If uptake is less than baseline scan,
score 4 and 5 are interpreted as PMR for iPET and RMD
for ePET. If uptake is greater than baseline or no change
or appearance of a new lesion, then score 4 and 5 are
interpreted as PMD and/or treatment failure.
Tumor response may be evaluated on the basis of
anatomical or metabolic metrics. Anatomical changes
although appear late and having limitation of
reproducibility, RECIST is the most commonly used
criteria globally. Metabolic changes which appear quite
early in phase of the treatment are more sensitive than
morphological changes. 18FDG uptake has a strong
correlation with viable tumor burden; and change in
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uptake has significantly high diagnostic accuracy
for predicting tumor response. PERCIST criteria must be
used for a precise and early prediction of tumor
response. However, lack of standardization in PET/CT
imaging protocols is the fundamental reason of dearth of
its popularity. For 18FDG avid lymphomas, Deauville
5-PS is the most reliable response evaluation criteria
which are being used for both Hodgkin and Non-Hodgkin
lymphomas worldwide. It is imperative that all existing
PET/CT facilities must work together to adopt same
imaging protocols to make subtle changes in 18FDG
tumor uptake more meaningful for better disease
outcome.
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